AC Immune Ltd Net Assets
AC Immune Ltd net assets. Based on the latest financial reports, AC Immune Ltd (ACIU) has net assets worth $31.53 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($137.42 Million) and total liabilities ($105.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ACIU shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $31.53 Million |
| % of Total Assets | 22.95% |
| Annual Growth Rate | 20.36% |
| 5-Year Change | -80.63% |
| 10-Year Change | -68.44% |
| Growth Volatility | 120.93 |
Net Assets of AC Immune Ltd (2013–2025)
Net assets of AC Immune Ltd from 2013 to 2025. This chart illustrates how AC Immune Ltd's net assets have evolved over time, based on quarterly financial data. See ACIU net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for AC Immune Ltd (2013–2025)
The table below shows the annual net assets of AC Immune Ltd from 2013 to 2025. For live market cap and overall valuation, see AC Immune Ltd (ACIU) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $44.93 Million | -59.98% |
| 2024-12-31 | $112.27 Million | -30.11% |
| 2023-12-31 | $160.64 Million | -4.94% |
| 2022-12-31 | $168.99 Million | -27.15% |
| 2021-12-31 | $231.98 Million | +7.66% |
| 2020-12-31 | $215.48 Million | -20.91% |
| 2019-12-31 | $272.44 Million | +53.38% |
| 2018-12-31 | $177.62 Million | +52.02% |
| 2017-12-31 | $116.84 Million | -17.94% |
| 2016-12-31 | $142.38 Million | +100.41% |
| 2015-12-31 | $71.04 Million | +202.74% |
| 2014-12-31 | $23.47 Million | +382.86% |
| 2013-12-31 | $4.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AC Immune Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36942773000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
AC Immune Ltd Net Assets Breakdown (December 2025)
AC Immune Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.26 Million | 5.02% |
| Other Comprehensive Income | $7.01K | 0.02% |
| Other Components | $482.19 Million | 1073.09% |
| Total Equity | $44.93 Million | 100.00% |
AC Immune Ltd Competitors by Market Cap
The table below lists competitors of AC Immune Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medallion Metals Ltd
AU:MM8
|
$209.74 Million |
|
Berkeley Energia Ltd
AU:BKY
|
$209.76 Million |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
$209.84 Million |
|
CHTC Helon Co Ltd
SHE:000677
|
$209.87 Million |
|
Hester Biosciences Limited
NSE:HESTERBIO
|
$209.64 Million |
|
Sweeten Real Estate Development Co Ltd
TW:5525
|
$209.60 Million |
|
Remedy Entertainment Oyj
HE:REMEDY
|
$209.56 Million |
|
Fresnillo PLC
LSE:FRES
|
$209.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AC Immune Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 112,270,000 to 44,934,988, a change of -67,335,012 (-60.0%).
- Net loss of 70,447,000 reduced equity.
- New share issuances of 6,000 increased equity.
- Other comprehensive income increased equity by 12,007.
- Other factors increased equity by 3,093,981.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-70.45 Million | -156.78% |
| Share Issuances | $6.00K | +0.01% |
| Other Comprehensive Income | $12.01K | +0.03% |
| Other Changes | $3.09 Million | +6.89% |
| Total Change | $- | -59.98% |
Book Value vs Market Value Analysis
This analysis compares AC Immune Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 21.27x to 4.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.10 | $2.06 | x |
| 2014-12-31 | $0.42 | $2.06 | x |
| 2015-12-31 | $1.28 | $2.06 | x |
| 2016-12-31 | $2.84 | $2.06 | x |
| 2017-12-31 | $2.04 | $2.06 | x |
| 2018-12-31 | $2.87 | $2.06 | x |
| 2019-12-31 | $3.83 | $2.06 | x |
| 2020-12-31 | $3.00 | $2.06 | x |
| 2021-12-31 | $3.10 | $2.06 | x |
| 2022-12-31 | $2.02 | $2.06 | x |
| 2023-12-31 | $1.90 | $2.06 | x |
| 2024-12-31 | $1.13 | $2.06 | x |
| 2025-12-31 | $0.45 | $2.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AC Immune Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1971.65%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 3.44x
- Recent ROE (-156.78%) is below the historical average (-45.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -286.01% | -130.17% | 0.68x | 3.24x | $-11.64 Million |
| 2014 | 45.78% | 35.50% | 1.00x | 1.29x | $8.40 Million |
| 2015 | 28.53% | 51.85% | 0.49x | 1.13x | $13.17 Million |
| 2016 | -4.98% | -30.57% | 0.15x | 1.10x | $-21.33 Million |
| 2017 | -22.60% | -130.39% | 0.15x | 1.13x | $-38.09 Million |
| 2018 | -28.68% | -708.24% | 0.04x | 1.11x | $-68.71 Million |
| 2019 | 16.68% | 41.14% | 0.37x | 1.10x | $18.20 Million |
| 2020 | -28.74% | -401.28% | 0.06x | 1.11x | $-83.47 Million |
| 2021 | -31.47% | -7732.63% | 0.00x | 1.13x | $-96.19 Million |
| 2022 | -41.87% | -1798.04% | 0.02x | 1.10x | $-87.65 Million |
| 2023 | -33.76% | -366.41% | 0.08x | 1.14x | $-70.30 Million |
| 2024 | -45.35% | -186.44% | 0.12x | 2.06x | $-62.14 Million |
| 2025 | -156.78% | -1971.65% | 0.02x | 3.44x | $-74.94 Million |
Industry Comparison
This section compares AC Immune Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $186,602,403
- Average return on equity (ROE) among peers: -32.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AC Immune Ltd (ACIU) | $31.53 Million | -286.01% | 3.36x | $209.65 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $26.13 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.61 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $17.31 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $792.42 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $26.12 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.41 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.53 Billion |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more